Additionally, on December 9, 2022 ObsEva filed a request to withdraw its previously announced moratorium with the Swiss court considering its over-indebtedness position has been resolved with the upfront proceeds of the Transaction.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OBSV:
- ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
- ObsEva to increase issued share capital by creating additional treasury shares
- ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
- ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
- ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million